Moberg Pharma begins patient enrollment in North American phase 3 study
Moberg Pharma AB (OMX: MOB) today announced that patient enrollment has started in the North American Phase 3 study for MOB-015 (nail fungus treatment).The randomized, multicenter, vehicle-controlled Phase 3 study will include approximately 350 patients in North America. The patients will be evaluated over 52 weeks and the primary endpoint will be the proportion of subjects achieving complete cure of their target nail. The study design builds on the experience gained from the previous Phase 3 studies. Moberg Pharma will cooperate with the same CRO, lead investigator and successful sites